Unknown

Dataset Information

0

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.


ABSTRACT: Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) with either carboplatin (AUC 6.0) and paclitaxel 200 mg/m2 (arm 1), docetaxel 75 mg/m2 (arm 2), or erlotinib 100 or 150 mg daily (arm 3); alternative schedules of MK-2206 135-200 mg QW or 90-250 mg Q3W were also tested.MTD of MK-2206 (N?=?72) was 45 mg QOD or 200 mg Q3W (arm 1); MAD was 200 mg Q3W (arm 2) and 135 mg QW (arm 3). DLTs included skin rash (arms 1, 3), febrile neutropenia (QOD, arms 1, 2), tinnitus (Q3W, arm 2), and stomatitis (QOD, arm 3). Common drug-related toxicities included fatigue (68%), nausea (49%), and rash (47%). Two patients with squamous cell carcinoma of the head and neck (arm 1; Q3W) demonstrated a complete and partial response (PR); additional PRs were observed in patients (1 each) with melanoma, endometrial, neuroendocrine prostate, NSCLC, and cervical cancers. Six patients had stable disease ?6 months.MK-2206 plus carboplatin and paclitaxel, docetaxel, or erlotinib was well-tolerated, with early evidence of antitumor activity.

SUBMITTER: Molife LR 

PROVIDER: S-EPMC3884022 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife L Rhoda LR   Yan Li L   Vitfell-Rasmussen Joanna J   Zernhelt Adriane M AM   Sullivan Daniel M DM   Cassier Philippe A PA   Chen Eric E   Biondo Andrea A   Tetteh Ernestina E   Siu Lillian L LL   Patnaik Amita A   Papadopoulos Kyriakos P KP   de Bono Johann S JS   Tolcher Anthony W AW   Minton Susan S  

Journal of hematology & oncology 20140103


<h4>Background</h4>Inhibition of AKT with MK-2206 has demonstrated synergism with anticancer agents. This phase 1 study assessed the MTD, DLTs, PK, and efficacy of MK-2206 in combination with cytotoxic and targeted therapies.<h4>Methods</h4>Advanced solid tumor patients received oral MK-2206 45 or 60 mg (QOD) with either carboplatin (AUC 6.0) and paclitaxel 200 mg/m2 (arm 1), docetaxel 75 mg/m2 (arm 2), or erlotinib 100 or 150 mg daily (arm 3); alternative schedules of MK-2206 135-200 mg QW or 9  ...[more]

Similar Datasets

| S-EPMC4342675 | biostudies-literature
| S-EPMC4592395 | biostudies-literature
| S-EPMC3988257 | biostudies-literature
| S-EPMC4515243 | biostudies-literature
| S-EPMC4233149 | biostudies-literature
| S-EPMC6182763 | biostudies-literature
| S-EPMC3979046 | biostudies-literature
| S-EPMC4891227 | biostudies-literature
| S-EPMC3772348 | biostudies-literature
2016-07-31 | E-GEOD-75087 | biostudies-arrayexpress